Contributions of hepatic gluconeogenesis suppression and compensative glycogenolysis on the glucose-lowering effect of CS-917, a fructose 1,6-bisphosphatase inhibitor, in non-obese type 2 diabetes goto-kakizaki rats

Journal of Pharmacological Sciences

Volumn 115, Issue 3, 2011, Pages 329-335

  Yoshida, Taishi ^a   Okuno, Akira ^a   Takahashi, Kanako ^a   Ogawa, Junko ^a   Hagisawa, Yuka ^a   Kanda, Shoichi ^a   Fujiwara, Toshihiko ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

Diabetes mellitus; Fructose 1,6 bisphosphatase; Gluconeogenesis; Glycogen phophorylase; Glycogenolysis

Indexed keywords

CP 91149; ENZYME INHIBITOR; FRUCTOSE BISPHOSPHATASE; GLUCOSE; GLYCOGEN; GLYCOGEN PHOSPHORYLASE INHIBITOR; LACTIC ACID; MANAGLINAT DIALANETIL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLYCOGEN LIVER LEVEL; GLYCOGENOLYSIS; GOTO KAKIZAKI RAT; INTESTINE; KIDNEY; LIVER; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RAT;

EID: 79952810784     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.10262FP     Document Type: Article

References (26)

1. Radziuk J, Pye S. Hepatic glucose uptake, gluconeogenesis and the regulation of glycogen synthesis. Diabetes Metab Res Rev. 2001;17:250-272. (Pubitemid 32821658)
2. Magnusson I, Rothman DL, Katz LD, Shulman RG, Shulman GI. Increased rate of gluconeogenesis in type II diabetes mellitus. A 13C nuclear magnetic resonance study. J Clin Invest. 1992;90:1323-1327.
3. Kurukulasuriya R, Link JT, Madar DJ, Pei Z, Rohde JJ, Richards SJ, et al. Prospects for pharmacologic inhibition of hepatic glucose production. Curr Med Chem. 2003;10:99-121. (Pubitemid 36138690)
4. Cherrington AD. Banting Lecture 1997. Control of glucose uptake and release by the liver in vivo. Diabetes. 1999;48:1198-1214.
5. Erion MD, van Poelje PD, Dang Q, Kasibhatla SR, Potter SC, Reddy MR, et al. MB06322 (CS-917): A potent and selective inhibitor of fructose 1,6-bisphosphatase for controlling gluconeogenesis in type 2 diabetes. Proc Natl Acad Sci U S A. 2005;102:7970-7975. (Pubitemid 40781047)
6. van Poelje PD, Potter SC, Linemeyer DL, Erion MD. MB06322 (CS-917) lowers blood glucose in rodents by inhibiting both hepatic and renal gluconeogenesis. Diabetes. 2006;55 Suppl 1:A137.
7. Dang Q, Kasibhatla SR, Raja Reddy K, Jiang T, Rami Reddy M, Potter SC, et al. Discovery of potent and specific fructose-1,6-bisphopshatase inhibitors and a series of orally-bioavailable phosphoramidase-sensitive prodrugs for the treatment of type 2 diabetes. J Am Chem Soc. 2007;129:15491-15502.
8. Yoshida T, Okuno A, Izumi M, Takahashi K, Hagisawa Y, Ohsumi J, et al. CS-917, a fructose 1,6-bisphosphatase inhibitor, improves postprandial hyperglycemia after meal loading in non-obese type 2 diabetic Goto-Kakizaki rats. Eur J Pharmacol. 2008;601:192-197.
9. Yoshida T, Okuno A, Tanaka J, Takahashi K, Nakashima R, Kanda S, et al. Metformin primarily decreases plasma glucose not by gluconeogenesis suppression but by activating glucose utilization in a non-obese type 2 diabetes Goto-Kakizaki rats. Eur J Pharmacol. 2009;623:141-147.
10. Bruce SR, Walker J, Feins K, Tao B, Triscari J. Initial safety, tolerability and glucose lowering of CS-917, a novel fructose 1,6-bisphosphatase (FBPase) inhibitor, in subjects with type 2 diabetes. Diabetelogia. 2006;49 Suppl 1:37.
11. Ekberg K, Landau BR, Wajngot A, Chandramouli V, Efendic S, Brunengraber H, et al. Contributions by kidney and liver to glucose production in the postabsorptive state and after 60 h of fasting. Diabetes. 1999;48:292-298. (Pubitemid 29061101)
12. Yánez AJ, Nualart F, Droppelmann C, Bertinat R, Brito M, Concha II, et al. Broad expression of fructose-1,6-bisphosphatase and phosphoenolpyruvate carboxykinase provide evidence for gluconeogenesis in human tissues other than liver and kidney. J Cell Physiol. 2003;197:189-197. (Pubitemid 37485247)
13. Mithieux G, Rajas F, Zitoun C. Glucose utilization is suppressed in the gut of insulin-resistant high fat-fed rats and is restored by metformin. Biochem Pharmacol. 2006;72:1257-1262.
14. Bailey CJ, Wilcock C, Day C. Effect of metformin on glucose metabolism in the splanchnic bed. Br J Pharmacol. 1992;105:1009-1013.
15. Bailey CJ, Mynett KJ, Page T. Importance of the intestine as a site of metformin-stimulated glucose utilization. Br J Pharmacol. 1994;112:671-675. (Pubitemid 24172918)
16. Aiston S, Hampson L, Gómez-Foix AM, Guinovart JJ, Agius L. Hepatic glycogen synthesis is highly sensitive to phosphorylase activity: evidence from metabolic control analysis. J Biol Chem. 2001;276:30479-30486.
17. Hassid WZ, Abraham S: Chemical procedures for analysis of polysaccharide I. Determination of glycogen and starch. Determination of glycogen with the anthron reagents. In: Colowick SP, Kaplan NO, editors. Methods in enzymology. 3rd ed. New York: Academic Press; 1957. p. 35-36.
18. Kurosaki E, Momose K, Nakano R, Shimaya A, Suzuki T, Shibasaki M, et al. Hypoglycemic agent YM440 ameliorates the impaired hepatic glycogenolysis after glucose loading by increasing glycogen synthase activity in obese Zucker rats. Jpn J pharmacol. 2002;89:274-281.
19. Gerich JE, Woerle HJ, Meyer C, Stumvoll M. Renal gluconeogenesis: its importance in human glucose homeostasis. Diabetes Care. 2001;24:382-391. (Pubitemid 32119142)
20. Meyer C, Stumvoll M, Nadkarni V, Dostou JM, Mitrakou A, Gerich JE. Abnormal renal, hepatic, and muscle glucose metabolism in type 2 diabetes. J Clin Invest. 1998;102:619-624. (Pubitemid 28376164)
21. Meyer C, Woerle HJ, Dostou JM, Welle SL, Gerich JE. Abnormal renal, hepatic, and muscle glucose metabolism following glucose ingestion in type 2 diabetes. Am J Physiol Endocrinol Metab. 2004;287:E1049-E1056. (Pubitemid 39491945)
22. Owen O, Felig P, Morgan A, Wahren J, Cahill G. Liver and kidney metabolism during prolonged starvation. J Clin Invest. 1969;48:574-583.
23. Eid A, Bodin S, Ferrier B, Delage H, Boghossian M, Martin M, et al. Intrinsic gluconeogenesis is enhance in renal tubules of Zucker diabetic fatty rats. J Am Soc Nephrol. 2006;17:398-405.
24. DeFronzo RA, Ferrannini E, Simonson DC. Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism. 1989;38:387-395. (Pubitemid 19105727)
25. Herling AW, Burger HJ, Schwab D, Hemmerle H, Below P, Schubert G. Pharmacodynamic profile of a novel inhibitor of the hepatic glucose-6- phosphatase system. Am J Physiol. 1998;274:G1087-G1093.
26. Shulman GI, Rothman DL, Smith D, Johnson CM, Blair JB, Shulman RG, et al. Mechanism of liver glycogen repletion in vivo by nuclear magnetic resonance spectroscopy. J Clin Invest. 1985;76:1229-1236. (Pubitemid 16225572)